Adjuvant therapy in completely resected non-small-cell lung cancer

Current Oncology Reports

Volumn 5, Issue 4, 2003, Pages 318-325

  Scagliotti, Giorgio V ^a   Novello, Silvia ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CANCER VACCINE; CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEFITINIB; IMMUNOLOGIC AGENT; LEVAMISOLE; LOMUSTINE; MITOMYCIN C; MUCIN 1; NAVELBINE; PACLITAXEL; UBEMINEX; UFT; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ANEMIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DATA ANALYSIS; DRUG MECHANISM; ESOPHAGITIS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; METASTASIS; NAUSEA AND VOMITING; NEUTROPENIA; POSTOPERATIVE CARE; RECURRENCE RISK; REVIEW; SURVIVAL TIME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CONTROLLED CLINICAL TRIAL; FEMALE; FOLLOW UP; LUNG RESECTION; LUNG TUMOR; MALE; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PNEUMONECTOMY; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0038334266     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0074-y     Document Type: Review

References (41)

1. Khuri JM, Spitz MR, Hong WK: Lung chemoprevention: targeting former rather than current smokers. Cancer Prev Int 1995, 2:55.
2. Levi F, Lucchini F, Negri E, et al.: Cancer mortality in Europe 1990-1994, and overview of trends from 1955 to 1994. Eur J Cancer 1999, 35:1477-1516.
3. Parkin DM, Pisani F, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999, 80:827-841.
4. Nesbitt JC, Putnam JB Jr, Walsh GL, et al.: Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 1995, 60:466-472.
5. Feld R, Rubenstein I, Weisenberger T, et al.: Sites of recurrence in resected stage I non-small cell lung cancer: a guide for future studies. J Clin Oncol 1984, 2:1352-1358.
6. Martini N, Flehinger B, Zaman M, et al.: Prospective study of 445 lung carcinomas with mediastinal lymph node metastases. J Thorac Cardiovasc Surg 1980, 80:390-397.
7. Pairolero, P, Williams D, Bergstralh M, et al.: Post-surgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984, 38:331-338.
8. Thomas P, Rubinstein L: Cancer recurrence after resection T1N0 non-small cell lung cancer. The Lung Cancer Study. Group. Ann Thorac Surg 1990, 48:242-247.
9. Pieterman RM, van Putten JW, Meuzelaar JL et al.: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000, 343:254-261.
10. Gupta NC, Graeber GM, Rogers JS II, et al.: Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg 1999, 229:286-291.
11. Weder W, Schmid RA, Bruchhaus H, et al.: Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998, 66:886-892.
12. Passlick B, Izbicki JR, Kubuschok B, et al.: Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis. Ann Thorac Surg 1996, 61:177-182.
13. Cote RJ, Hawes D, Chaiwun B, et al.: Detection of occult metastases in lung carcinomas: progress and implications for lung cancer staging. J Surg Oncol 1998, 69:265-274.
14. Ohgami A, Mitsudomi T, Sugio K, et al.: Micrometastatic tumour cells in the bone marrow of patients with non-small cell lung cancer. Ann Thorac Surg 1997, 64:363-367.
15. Passlick B, Kubuschok B, Izbicki JR et al.: Isolated tumour cells in the bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann Thorac Surg 1999, 68:2053-2058.
16. PORT Meta-analysis Trialists Group: Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet 1998, 352:257-263.
17. Machtay M, Lee JH, Shrager JB, et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small cell lung carcinoma. J Clin Oncol 2001, 19:3912-3917.
18. Wagner H Jr, Bonomi P: Preoperative and postoperative therapy for non-small cell lung cancer. In Thoracic Oncology, edn 2. Edited by Roth JA, Ruckdeschel JC, Weisenburger TH. Philadelphia: WB Saunders Co.; 1995:147-163.
19. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995, 311:899-909.
20. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic and immune therapy. Lancet 1992, 339:1-15, 71-85.
21. Keller SM, Adak S, Wagner H, et al.: A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. N Engl J Med 2000, 343:1217-1222.
22. Tonato M, on behalf of the ALPI/EORTC-LCCG investigators: Final report of the Adjuvant Lung Project Italy (ALPI): an Italian/EORTC-LCCG randomised trial of adjuvant chemotherapy in completely resected non-small cell lung cancer [abstract]. Proc ASCO 2002, 21:290a.
23. Pisters KM, Ginsberg RJ, Giroux DJ, et al.: Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 2000, 119:429-439.
24. The Study Group of Adjuvant Chemotherapy for Lung Cancer: A randomised trial of postoperative adjuvant chemotherapy in non-small cell lung cancer. Eur J Surg Oncol 1995, 21:69-77.
25. Wada H, Hitami S, Teramatsu T, et al.: Adjuvant chemotherapy after complete resection in non-small cell lung cancer. J Clin Oncol 1996, 14:1048-1054.
26. Wada H, Miyahara R, Tanaka F, et al.: Postoperative adjuvant chemotherapy with PVM and UFT in resected stage I-II NSCLC: a randomised clinical trial. Eur J Cardiothorac Surg 1999, 15:438-443.
27. Kato H, Konaka C, Tsuboi M., et al.: A randomised phase III study comparing ubeminex (Bestatin) versus placebo as post-operative adjuvant treatment in patients with stage I squamous cell lung cancer [abstract]. Proc ASCO 2001, 20:307a.
28. Rusch V. Baselga J, Cordon-Cardo C, et al.: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1995, 53:2379-2385.
29. Fontanini G, De Laurentis M, Vignati S, et al.: Evaluation of epidermal growth factor-related growth factors and receptors and of neo-angiogenesis in completely resected stage I-IIIA non-small cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998, 4:241-249.
30. Veale D, Kerr N, Gibson GJ, et al.: The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer 1993, 68:162-165.
31. Reissmann PT, Koga H, Figlin RA, et al.: Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol 1999, 125:61-70.
32. Dannenberg AJ, Altorki NK, Boyle JO: Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001, 2:544-551.
33. Meyer UA: Pharmacogenetics and adverse drug reactions. Lancet 2000, 356:1667-1671.
34. Slebos RJC, Hruban RH, Dalesio O, et al.: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990, 323:561-565.
35. Huncharek M, Muscat J, Geschwind JF: K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 1999, 20:1507-1510.
36. Scagliotti GV, Masiero P, Pozzi E: Biological prognostic factors in non-small cell lung cancer. Lung Cancer 1995, 12(Suppl 1):S13-S25
37. Robertson KD: DNA methylation, methyltransferases and cancer. Oncogene 2001, 20:3139-3155.
38. Zochbauer-Muller S, Fong KM, Virmani AK, et al.: Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001, 61:249-255.
39. Herbst RS, Yano S, Kuniyasu H, et al.: Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res 2000, 6:790-797.
40. Tang X, Khuri Fr, Lee JJ, et al.: Hypermethylation of the death-associated protein kinase promoter and aggressiveness in stage I non-small cell lung cancer. J Natl Cancer Inst 2000, 92:1511-1516.
41. Chang YS, Wang L, Liu D, et al.: Correlation between insulin-growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 2002, 8:3669-3675.